Seattle-area psychedelics startup CaaMTech raises $22M to advance to human testing

Seattle-area psychedelics startup CaaMTech raises $22M to advance to human testing

CaaMTech aims to take the uncertainty out of psychedelics like magic mushrooms and to provide defined formulations. (BigStock photo) CaaMTech, a Seattle-area startup developing new psychedelic agents, has raised $ 22 million in funding, the company announced this week. The company synthesizes a number of new compounds that are similar to those found in “magic … Read more

Gap year student secures last open seat for Blue Origin’s first human spaceflight – TechCrunch

Gap year student secures last open seat for Blue Origin’s first human spaceflight – TechCrunch

To get a roundup of TechCrunch’s greatest and most important stories delivered to your inbox every day at 3:00 p.m. PDT, subscribe here. Hello and welcome to Daily Crunch for July 15, 2021. Good news from the TechCrunch front: The agenda for our big disrupt conference in September is set. It’s going to be incredible, … Read more

Jeff Bezos’ Blue Origin auctions off seat on first human spaceflight for $28M – TechCrunch

Jeff Bezos’ Blue Origin auctions off seat on first human spaceflight for $28M – TechCrunch

Blue Origin has its winner for its first manned spaceflight, and the winner will pay $ 28 million for the privilege of flying aboard the company’s first private astronaut mission. The winning bid came today during a live auction in which 7,600 registered bidders from 159 countries competed for place. This was the culmination of … Read more

Ultrapotent, nanoparticle COVID-19 vaccine with Univ. of Wash. roots gets $173M for human trials

Ultrapotent, nanoparticle COVID-19 vaccine with Univ. of Wash. roots gets $173M for human trials

An image of the nanoparticle with spike proteins used in a newly developed COVID-19 vaccine candidate. (Ian Haydon / UW Institute for Protein Design) A project to test what is known as an ultrapotent second-generation COVID-19 vaccine candidate will receive up to $ 173.4 million to conduct Phase 3 clinical trials. The vaccine was developed … Read more